Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23840463,maximal response (EC50),The estimate of peginesatide drug concentration required for 50% of maximal response (EC50) estimates was 0.4 µg/mL.,A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23840463/),[μg] / [ml],0.4,52510,DB08894,Peginesatide
,23318685,cumulative radioactivity recovery,"At 2 weeks after dosing, cumulative radioactivity recovery in the urine and feces was 60 and 7% of the administered dose, respectively, with most of the radioactivity associated with the parent molecule.","Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318685/),%,60,184094,DB08894,Peginesatide
,23318685,cumulative radioactivity recovery,"At 2 weeks after dosing, cumulative radioactivity recovery in the urine and feces was 60 and 7% of the administered dose, respectively, with most of the radioactivity associated with the parent molecule.","Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23318685/),%,7,184095,DB08894,Peginesatide
